• No se han encontrado resultados

CAPÍTULO III: SUSTENTACIÓN

3.3. Ideas centrales por pieza

H. pylori and E. coli strains used in this study, and their relevant characteristics

are shown in Table 2.1. H. pylori was identified by morphology, Gram

staining and urease testing. The strains used in this study were isolated and

typed by myself, J. Hale, J. Rhead, S. Patel and A. Memon. Table 2.2 shows

the details of the plasmids used in this study and their relevant

2-69

Table 2.1 Bacterial strains

Strain Relevant characteristics Reference/Source

N XG Z Electrocompetent cells F- mcrA mrr-hsdRMS-mcrBC) A A ) M X D - U K L G - tonA Novagen

60190 Wild-type, VacA type s1/m1, Tox+ Leunk et al. (1988) 60190/A130 As 60190. except vacA::km Cover et al, 1994 60190 pCTB2::cat pBluescript containing 3 cysS to vacA nt 274 from strain

60190. cat inserted into Hind III site immediately 3 to cysS ; AmpR; CmR

Letley et al. (2003)

60190 P(-6)G As 60190 pCTB2::cat except proline replaced with glycine at position -6 of the signal sequence.

D.P. Letley

60190 S(-3)L As 60190 pCTB2::cat except serine replaced with leucine at position -3 of the signal sequence.

D.P. Letley

60190 P(-6)GS(-3)L As 60190 pCTB2::cat except proline replaced with glycine at position -6, and serine replaced with leucine at position -3 of the signal sequence.

D.P. Letley

Tx30a Wild-type, VacA type s2/m2, Tox- Leunk et al. (1988) Tx30a pA153::cat As Tx30a but cat cysS; CmR Letley et al. (2003) Tx30a G(-6)P As Tx30a pA153::cat except glycine replaced with proline at

position -6 of the signal sequence.

D.P. Letley

Tx30a L(-3)S As Tx30a pA153::cat except leucine replaced with serine at position -6 of the signal sequence.

D.P. Letley

Tx30a G(-6)PL(-3)S As Tx30a pA153::cat except glycine replaced with proline at position -6, and leucine replaced with serine at position -3 of the signal sequence.

D.P. Letley

60190 G(-6)PL(-3)S As Tx30a G(-6)PL(-3)S but with plasmid transformed into a 60190 strain background.

D.P. Letley and C.G. Masters (This study). Tx30a P(-6)GS(-3)L As 60190 P(-6)GS(-3)L but with plasmid transformed into a

Tx30a strain background.

D.P. Letley and C.G. Masters (This study). 60190/ SL As pCTB2::cat except stem loop deleted from vacA nt 608 to

704 and replaced with a Bgl II site; AmpR; CmR

G.L. Narayanan

60190/SL GtoA As 60190 pCTB2::cat except with G at position +28 within the vacA UTR A

This study

60190/IRDIS As 60190 pCTB2::cat except with a 6bp disruption in an

-35

motif of the vacA promoter.

This study

45B Clinical strain isolated from corpus. vacA type s1/m1/i1,

cagA +.

This study

46B Clinical strain isolated from corpus. vacA type s1/m1/i1,

cagA -.

This study

72B Clinical strain isolated from corpus. vacA type s1/m1/i1,

cagA +.

This study

73B Clinical strain isolated from corpus. vacA type s1/m2/i2,

cagA +.

This study

77B Clinical strain isolated from corpus. vacA type s1/m1/i1,

cagA +.

This study

83B Clinical strain isolated from corpus. vacA type s1/m1/i1,

cagA +.

This study

86B Clinical strain isolated from corpus. vacA type s1/m1/i1,

cagA +.

This study

93B Clinical strain isolated from corpus. vacA type s1/m2/i1,

cagA

2-70

120B Clinical strain isolated from corpus. vacA type s1/m1/i1,

cagA +.

This study

121B Clinical strain isolated from corpus. vacA type s1/m1/i1,

cagA +.

This study

122B Clinical strain isolated from corpus. vacA type s1/m1/i2,

cagA +.

This study

124B Clinical strain isolated from corpus. vacA type s1/m1/i1,

cagA +.

This study

126B Clinical strain isolated from corpus. vacA type s1/m2/i1,

cagA +.

This study

173B Clinical strain isolated from corpus. vacA type s1/m1/i1,

cagA +.

This study

181B Clinical strain isolated from corpus. vacA type s1/m1/m2/i2,

cagA -.

This study

182B Clinical strain isolated from corpus. vacA type s1/m1/i1,

cagA -.

This study

187B Clinical strain isolated from corpus. vacA type s1/m1/i1,

cagA +.

This study

192B Clinical strain isolated from corpus. vacA type s1/m1/i1,

cagA +.

This study

194B Clinical strain isolated from corpus. vacA type s1/m2/i1,

cagA -.

This study

201B Clinical strain isolated from corpus. vacA type s1/m1/i1,

cagA +.

This study

206B Clinical strain isolated from corpus. vacA type s1/m1/i1,

cagA +.

This study

215B Clinical strain isolated from corpus. vacA type s1/m1/i1,

cagA +.

This study

218B Clinical strain isolated from corpus. vacA type s1/m1/i1,

cagA +.

This study

221B Clinical strain isolated from corpus. vacA type s1/m2/i2,

cagA -.

This study

223B Clinical strain isolated from corpus. vacA type s2/m2/i2,

cagA -.

This study

233B Clinical strain isolated from corpus. vacA type s2/m2/i2,

cagA +.

This study

240B Clinical strain isolated from corpus. vacA type s1/m1/i1,

cagA +.

This study

242B Clinical strain isolated from corpus. vacA type s2/m2/i2,

cagA -.

This study

247B Clinical strain isolated from corpus. vacA type s1/m1/i1,

cagA +.

This study

249B Clinical strain isolated from corpus. vacA type s1/m2/i1/i2,

cagA +.

This study

253B Clinical strain isolated from corpus. vacA type s1/m1/i1,

cagA +.

2-71

255B Clinical strain isolated from corpus. vacA type s1/m1/i1,

cagA +.

This study

256B Clinical strain isolated from corpus. vacA type s2/m2/i2,

cagA +.

This study

265B Clinical strain isolated from corpus. vacA type s1/m2/i2,

cagA +.

This study

271B Clinical strain isolated from corpus. vacA type s1/m1/i1,

cagA -.

This study

274B Clinical strain isolated from corpus. vacA type s1/m1/i1,

cagA +.

This study

308B Clinical strain isolated from corpus. vacA type s1/m2/i2,

cagA -.

This study

320B Clinical strain isolated from corpus. vacA type s1/m2/i2,

cagA -.

This study

322B Clinical strain isolated from corpus. vacA type s1/m1/i1,

cagA +.

This study

326B Clinical strain isolated from corpus. vacA type s1/i2/m2,

cagA -.

This study

335B Clinical strain isolated from corpus. vacA type s1/m1/i1,

cagA +.

This study

350B Clinical strain isolated from corpus. vacA type s1/m2/i1,

cagA +.

This study

Table 2.2 Plasmids

Name Construct Resistance Reference/Source

pCTB2::cat pBluescript containing 3

cysS to vacA nt 274 from

strain 60190. cat inserted into Hind III site

immediately 3 to cysS ; AmpR; CmR Ampicillin, chloramphenicol Letley et al, 2000 pCTB2::cat P(-6)GS(-3)L As 60190 pCTB2::cat except proline replaced with glycine at position -6, and serine replaced with leucine at position -3 of the signal sequence.

Ampicillin, chloramphenicol

Letley et al, 2000

pCTB2::cat SL As pCTB2::cat except stem loop deleted from vacA nt 608 to 704 and replaced with a Bgl II site; AmpR; CmR.

Ampicillin, chloramphenicol

G.L. Narayanan 2005

2-72

Documento similar